Skip to content
Home/Companies/Biotech/Ducentis BioTherapeutics

Ducentis BioTherapeutics

Biotech·UK·Exited 2022·Held 3yr
Entry
2019
Hold
3yr
Exit
2022

Who owns Ducentis BioTherapeutics?

Ducentis BioTherapeutics was owned by LifeArc through LifeArc Ventures (1992 vintage) from 2019 to 2022, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-05-31

LifeArc
Investor
LifeArc
LifeArc Ventures · 1992 · Life Sciences VC

Key facts

HQUK
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2022

More from LifeArc Ventures

Other portfolio companies in the same fund.

Exciva
Active
BiotechGermany· 2026
GlycoEra
Active
BiotechSwitzerland· 2025
Hillstar Bio
Active
BiotechUnited States· 2025
Tribune Therapeutics
Active
BiotechSweden· 2025
Fluid Biomed
Fluid Biomed
Active
MedTechCanada· 2024
Affect Therapeutics
Affect Therapeutics
Active
HealthTechUnited States· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Ducentis BioTherapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Ducentis BioTherapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue